1. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial 
Jing-Xin Li, PhD, Li-Hua Hou, PhD, Fan-Yue Meng, MSc, Shi-Po Wu, PhD, Yue-Mei Hu, BS, Qi Liang, BS, Kai Chu, MSc, Zhe Zhang, BS, Jun-Jie Xu, PhD, Rong Tang, MSc, Wen-Juan Wang, MSc, Prof Pei Liu, PhD, Jia-Lei Hu, MSc, Li Luo, MSc, Rong Jiang, MSc, Feng-Cai Zhu, MSc, Wei Chen, PhD 
The Lancet Global Health 
Volume 5, Issue 3, Pages e324-e334 (March 2017)
DOI: /S X(16)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

2. Figure 1 Trial profiles of the initial study and the booster study.
High-dose vaccine= adenovirus type-5 Ebola virus vaccines of 1·6 × 1011 viral particles. Low-dose vaccine=adenovirus type-5 Ebola virus vaccines of 4·0×1010 viral particles.
The Lancet Global Health 2017 5, e324-e334DOI: ( /S X(16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

3. Figure 2 Ebola-specific ELISA EC90 titres to glycoprotein
GMT= geometric mean titre (A) all participants, (B) patients with baseline adenovirus type-5 neutralising antibody titres, (C) patients with baseline adenovirus type-5 neutralising antibody titres >1:200.
The Lancet Global Health 2017 5, e324-e334DOI: ( /S X(16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

4. Figure 3
Glycoprotein-specific T-cell response measured by Enzyme-Linked ImmunoSpot at different time points before and after prime and boost vaccination
(A) IFN-γ expressing T cells per 106 PBMC. (B) proportion of participants with a positive response of IFN-γ expressing T cells. IFN=interferon. PBMC=peripheral blood mononuclear cells.
The Lancet Global Health 2017 5, e324-e334DOI: ( /S X(16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions